PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Passage BIO, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$3.58+0.08 (+2.29%)
Close on Oct 19, 2026
- Market cap
- $11.49M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
4M of 3M shares
Institutional holders
30
5 new, 9 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
1 buys · 2 sales
Net bought $93.04K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Weston Nichols | 673,759 | 21.00% | 13D (active) | Jun 25, 2026 |
| Lynx1 Capital Management LP | 623,704 | 19.60% | 13G (passive) amendment | Sep 30, 2025 |
| Orbimed Capital Gp Vii LLC | 243,878 | 7.82% | 13D (active) amendment | Jul 17, 2025 |
| David Paolella | 235,058 | 7.30% | 13G (passive) | Jun 18, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PASG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 2,886,125 | 89.69% | $4.31M | New | 0.00% |
| Lynx1 Capital Management LP | 673,759 | 20.94% | $3.29M | +50,055 | 0.38% |
| Vanguard Capital Management LLC | 113,964 | 3.54% | $556.14K | – | 0.00% |
| Balyasny Asset Management L.P. | 107,025 | 3.33% | $522.28K | New | 0.00% |
| Ikarian Capital, LLC | 99,517 | 3.09% | $485.64K | +31,393 | 0.05% |
| Yiheng Capital Management, L.P. | 86,097 | 2.68% | $420.15K | – | 0.14% |
| Renaissance Technologies LLC | 47,892 | 1.49% | $233.71K | −85,720 | 0.00% |
| Erste Asset Management GmbH | 40,665 | 1.26% | $197.23K | −44,597 | 0.00% |
| Geode Capital Management, LLC | 37,026 | 1.15% | $180.72K | −4,354 | 0.00% |
| Verdad Advisers, LP | 30,728 | 0.95% | $149.95K | +8,600 | 0.14% |
| Boothbay Fund Management, LLC | 28,439 | 0.88% | $138.78K | +9,568 | 0.00% |
| BlackRock, Inc. | 27,910 | 0.87% | $136.20K | −685 | 0.00% |
| Acadian Asset Management LLC | 22,496 | 0.70% | $109 | −1,700 | 0.00% |
| Vanguard Fiduciary Trust Co | 17,049 | 0.53% | $83.20K | – | 0.00% |
| Deltec Asset Management LLC | 15,000 | 0.47% | $73.20K | New | 0.01% |
| UBS Group AG | 13,565 | 0.42% | $66.20K | −13,936 | 0.00% |
| Hrt Financial LP | 12,712 | 0.40% | $62 | New | 0.00% |
| Fiduciary Trust Co | 10,750 | 0.33% | $52.46K | – | 0.00% |
| Gts Securities LLC | 10,000 | 0.31% | $48.80K | New | 0.00% |
| Morgan Stanley | 2,389 | 0.07% | $11.66K | −261 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 30 | 4M | 100.0% | 5 / 5 | 7 / 9 | 3M | 1M |
| Q1 2026 | 35 | 2M | 55.3% | 12 / 6 | 4 / 6 | 0M | 0M |
| Q4 2025 | 30 | 2M | 49.0% | 6 / 5 | 6 / 7 | 0M | 0M |
| Q3 2025 | 31 | 2M | 48.5% | 29 / 0 | 2 / 0 | 2M | 0M |
| Q2 2025 | 2 | 0M | 0.1% | 2 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PASG | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 78,764 | 2.45% | $384.37K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 35,200 | 1.09% | $171.78K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 18,535 | 0.58% | $106.95K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 6,427 | 0.20% | $37.08K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 4,783 | 0.15% | $27.60K | 0.00% | May 31, 2026 |
| LVIP Dimensional U.S. Core Equity 2 Fund | 2,022 | 0.06% | $9.87K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 1,897 | 0.06% | $10.95K | 0.00% | May 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 792 | 0.02% | $3.54K | 0.00% | Jul 31, 2026 |
| Diversified Equity Alpha Master Portfolio | 504 | 0.02% | $2.46K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| William Chou | PRESIDENT AND CEO, Director | 6,524 | 0.20% | Mar 18, 2026 |
| Kathleen Borthwick | CFO | 5,402 | 0.17% | Mar 18, 2026 |
| Edgar B. Cale | GC & CORPORATE SECRETARY | 45,995 | 1.43% | Mar 18, 2025 |
| Athena Countouriotis | Director | 18,900 | 0.59% | May 21, 2026 |
| Derrell Porter | Director | – | – | May 21, 2026 |
| Thomas Richard Kassberg | Director | – | – | May 21, 2026 |
| Maxine Gowen | Director | – | – | May 21, 2026 |
| Sandip Kapadia | Director | 0 | – | May 21, 2026 |
| Dolan Sondhi | Director | – | – | May 21, 2026 |
| Saqib Islam | Director | 5,000 | 0.16% | May 30, 2025 |
| Weston Nichols | 10% owner | 673,759 | 20.94% | Jun 29, 2026 |
| Capital Management LP Lynx1 | 10% owner | 591,696 | 18.39% | Jun 29, 2026 |
| Capital GP VII LLC OrbiMed | 10% owner | 6,885,572 | 213.98% | Jun 26, 2025 |
| Advisors Llc Orbimed | 10% owner | 6,066,343 | 188.52% | Jun 26, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Weston Nichols 10% owner | Jun 25, 2026 | Buy | +50,055 | $4.12 | $206.23K | 673,759 |
| William Chou PRESIDENT AND CEO, Director | Jan 8, 2026 | Sale | −4,076 | $18.44 | $75.16K | 6,524 |
| William Chou PRESIDENT AND CEO, Director | Jan 8, 2026 | Option exercise | +10,000 | – | – | 10,600 |
| Kathleen Borthwick CFO | Jan 8, 2026 | Sale | −2,062 | $18.44 | $38.02K | 5,402 |
| Kathleen Borthwick CFO | Jan 8, 2026 | Option exercise | +5,000 | – | – | 7,464 |
| Weston Nichols 10% owner | Sep 15, 2025 | Buy | +11,900 | $6.99 | $83.18K | 623,704 |
| Weston Nichols 10% owner | Sep 12, 2025 | Buy | +19,783 | $6.99 | $138.28K | 611,804 |
| Weston Nichols 10% owner | Sep 11, 2025 | Buy | +325 | $6.96 | $2.26K | 592,021 |
| Capital Management LP Lynx1 10% owner | Jul 24, 2025 | Buy | +66,423 | $5.71 | $379.28K | 591,696 |
| Capital Management LP Lynx1 10% owner | Jul 23, 2025 | Buy | +49,302 | $5.74 | $282.99K | 525,273 |
| Capital Management LP Lynx1 10% owner | Jul 22, 2025 | Buy | +13,123 | $5.44 | $71.39K | 475,971 |
| Advisors Llc Orbimed 10% owner | Jun 26, 2025 | Sale | −213,257 | $0.33 | $70.37K | 6,066,343 |
| Advisors Llc Orbimed 10% owner | Jun 25, 2025 | Sale | −138,800 | $0.33 | $45.80K | 6,279,600 |
| Advisors Llc Orbimed 10% owner | Jun 24, 2025 | Sale | −231,600 | $0.35 | $81.06K | 6,418,400 |
| Advisors Llc Orbimed 10% owner | Apr 24, 2025 | Sale | −68,195 | $0.32 | $21.82K | 6,650,000 |
| Advisors Llc Orbimed 10% owner | Apr 23, 2025 | Sale | −89,328 | $0.34 | $30.37K | 6,718,195 |
| Advisors Llc Orbimed 10% owner | Apr 22, 2025 | Sale | −78,049 | $0.34 | $26.54K | 6,807,523 |
| Capital GP VII LLC OrbiMed 10% owner | Apr 17, 2025 | Sale | −77,090 | $0.33 | $25.44K | 6,885,572 |
| Capital GP VII LLC OrbiMed 10% owner | Apr 16, 2025 | Sale | −61,638 | $0.33 | $20.34K | 6,962,662 |
| Capital GP VII LLC OrbiMed 10% owner | Apr 15, 2025 | Sale | −10,326 | $0.38 | $3.92K | 7,024,300 |
| Kathleen Borthwick CFO | Feb 11, 2025 | Sale | −3,183 | $0.53 | $1.69K | 41,283 |
| Kathleen Borthwick CFO | Feb 10, 2025 | Option exercise | +8,000 | – | – | 44,466 |
| Advisors Llc Orbimed 10% owner | Jan 14, 2025 | Sale | −79,024 | $0.60 | $47.41K | 7,034,626 |
| Advisors Llc Orbimed 10% owner | Jan 13, 2025 | Sale | −17,986 | $0.64 | $11.51K | 7,113,650 |
| Advisors Llc Orbimed 10% owner | Jan 10, 2025 | Sale | −126,209 | $0.66 | $83.30K | 7,131,636 |
| Capital GP VII LLC OrbiMed 10% owner | Jan 8, 2025 | Sale | −75,007 | $0.68 | $51.00K | 7,257,845 |
| Capital GP VII LLC OrbiMed 10% owner | Jan 7, 2025 | Sale | −52,536 | $0.71 | $37.30K | 7,332,852 |
| Capital GP VII LLC OrbiMed 10% owner | Jan 6, 2025 | Sale | −19,481 | $0.77 | $15.00K | 7,385,388 |
| Capital Management LP Lynx1 10% owner | Dec 27, 2024 | Buy | +373,645 | $0.65 | $242.87K | 9,256,953 |
| Capital GP VII LLC OrbiMed 10% owner | Dec 20, 2024 | Sale | −230,321 | $0.60 | $138.19K | 7,404,869 |
| Advisors Llc Orbimed 10% owner | Dec 11, 2024 | Sale | −80 | $0.80 | $64 | 7,635,190 |
| Advisors Llc Orbimed 10% owner | Dec 10, 2024 | Sale | −8,015 | $0.80 | $6.41K | 7,635,270 |
| Advisors Llc Orbimed 10% owner | Dec 9, 2024 | Sale | −54,181 | $0.84 | $45.51K | 7,643,285 |
| Capital GP VII LLC OrbiMed 10% owner | Dec 6, 2024 | Sale | −20,903 | $0.82 | $17.14K | 7,697,466 |
| Capital GP VII LLC OrbiMed 10% owner | Dec 4, 2024 | Sale | −76,200 | $0.79 | $60.20K | 7,718,369 |
| Capital Management LP Lynx1 10% owner | Nov 27, 2024 | Buy | +29,300 | $0.67 | $19.63K | 8,883,308 |
| Capital Management LP Lynx1 10% owner | Nov 26, 2024 | Buy | +167,055 | $0.71 | $118.61K | 8,854,008 |
| Capital Management LP Lynx1 10% owner | Nov 25, 2024 | Buy | +259,998 | $0.56 | $145.60K | 8,686,953 |
| Advisors Llc Orbimed 10% owner | Sep 19, 2024 | Sale | −39,300 | $0.71 | $27.90K | 7,794,569 |
| Capital GP VII LLC OrbiMed 10% owner | Sep 18, 2024 | Sale | −25,631 | $0.73 | $18.71K | 7,833,869 |
| Capital GP VII LLC OrbiMed 10% owner | Sep 17, 2024 | Sale | −111,400 | $0.73 | $81.32K | 7,859,500 |
| Capital GP VII LLC OrbiMed 10% owner | Sep 16, 2024 | Sale | −63,100 | $0.74 | $46.69K | 7,970,900 |
| Kathleen Borthwick SVP, INTERIM CFO | Feb 13, 2024 | Sale | −1,470 | $0.97 | $1.43K | 28,466 |
| Mark S. Forman CHIEF MEDICAL OFFICER | Feb 13, 2024 | Sale | −1,638 | $0.97 | $1.59K | 48,631 |
| Kathleen Borthwick SVP, INTERIM CFO | Feb 10, 2024 | Option exercise | +4,000 | – | – | 29,936 |
| Mark S. Forman CHIEF MEDICAL OFFICER | Feb 10, 2024 | Option exercise | +5,000 | – | – | 50,269 |
| Kathleen Borthwick SVP, Interim CFO | Jan 2, 2024 | Sale | −10,672 | $0.91 | $9.71K | 25,936 |
| Mark S. Forman Chief Medical Officer | Jan 2, 2024 | Sale | −15,813 | $0.91 | $14.39K | 45,269 |
| Edgar B. Cale GC & Corporate Secretary | Jan 2, 2024 | Sale | −15,813 | $0.91 | $14.39K | 45,995 |
| Kathleen Borthwick SVP, Interim CFO | Dec 31, 2023 | Option exercise | +30,000 | – | – | 36,608 |
| Mark S. Forman Chief Medical Officer | Dec 31, 2023 | Option exercise | +50,000 | – | – | 61,082 |
| Edgar B. Cale GC & Corporate Secretary | Dec 31, 2023 | Option exercise | +50,000 | – | – | 61,808 |
| Simona King Chief Financial Officer | Jul 28, 2023 | Sale | −11,453 | $0.88 | $10.08K | 23,994 |
| Simona King Chief Financial Officer | Jul 28, 2023 | Option exercise | +31,250 | – | – | 35,447 |
| Advisors Llc Orbimed 10% owner | Jun 28, 2023 | Buy | +575,195 | $0.84 | $483.16K | 8,034,000 |
| Advisors Llc Orbimed 10% owner | Jun 27, 2023 | Buy | +617,382 | $0.84 | $518.60K | 7,458,805 |
| Alexandros Fotopoulos Chief Technical Officer | Jun 16, 2023 | Sale | −4,052 | $0.93 | $3.77K | 28,693 |
| Alexandros Fotopoulos Chief Technical Officer | Jun 15, 2023 | Option exercise | +12,500 | – | – | 32,745 |
| Simona King Chief Financial Officer | Apr 18, 2023 | Sale | −2,053 | $1.05 | $2.16K | 2,053 |
| Simona King Chief Financial Officer | Apr 18, 2023 | Option exercise | +6,250 | – | – | 6,250 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| William Chou Officer | Jan 9, 2026 | 4,076 | $75.12K | Jan 9, 2026 | Restricted Stock |
| OrbiMed Private Investments VII, LP Stockholder | Jul 21, 2025 | 132,645 | $737.51K | Jul 21, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Jul 15, 2025 | 53,293 | $361.86K | Jul 15, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Jul 7, 2025 | 259,000 | $112.15K | Jul 7, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Jun 24, 2025 | 1,076,120 | $378.36K | Jun 24, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Apr 15, 2025 | 787,179 | $301.49K | Apr 15, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Jan 6, 2025 | 1,140,740 | $945.67K | Jan 6, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Dec 4, 2024 | 2,985,518 | $2.66M | Dec 4, 2024 | IPO |
| Healthcare Trust PLC Worldwide Stockholder | Dec 4, 2024 | 2,028,307 | $1.81M | Dec 4, 2024 | IPO |
| OrbiMed Private Investments VII, LP Owner | Sep 16, 2024 | 927,572 | $748.55K | Sep 16, 2024 | IPO |
| Healthcare Trust PLC Worldwide Owner | Sep 16, 2024 | 241,328 | $194.75K | Sep 16, 2024 | IPO |